NEW YORK (TheStreet) -- Ohr Pharmaceuticals (OHRP) soared Thursday after Vista Partners increased its price target on the stock to $31 from $14.
The stock plunged Tuesday after it reported results of its phase II study on its Squalamine eye drop. For more on that, read TheStreet's Adam Feuerstein's article here.
Ohr closed up 35.43%, or $2.59, to $9.90 on Thursday. More than 5.7 million shares changed hands, compared to the average volume of 401,319.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts